pyrazines has been researched along with Invasiveness, Neoplasm in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bamodu, OA; Chao, TY; Haryana, SM; Hsiao, M; Hsu, WM; Liu, YL; Pikatan, NW; Yeh, CT | 1 |
| Du, W; Gao, A; Guo, M; Herman, JG; Jiao, S; Wang, L; Zhang, L | 1 |
| Ji, Z; Li, H; Xiao, Y; Yan, W; Zhou, Y; Zhou, Z | 1 |
| Annunziata, CM; Bagheri, MH; Botesteanu, DA; Ekwede, I; Harrell, MI; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Merino, MJ; Minasian, L; Nair, J; Steinberg, SM; Swisher, EM; Trepel, JB; Zimmer, A | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Zhang, J; Zhong, Y | 1 |
| Chang, LC; Chang, TC; Huang, FC; Kuo, MH; Lin, JJ; Tseng, TY; Wang, JM; Wang, ZF; Yen, SJ | 1 |
| Chiappetta, G; Di Maro, G; Jarzab, B; Masullo, M; Monaco, M; Oczko-Wojciechowska, M; Orlandella, FM; Salerno, P; Salvatore, G; Santoro, M; Thomas, G; Unger, K | 1 |
| Demosthenous, C; Dogan, A; Gupta, M; Han, JJ; Hege, K; Link, B; Maurer, MJ; Sotomayor, E; Stenson, MJ; Wellik, LE; Witzig, T | 1 |
| Jones, DR; Liu, Y; Nagji, AS; Taylor, MD; Theodosakis, N | 1 |
| Adachi, K; Endoh, A; Nakamura, R; Oda, Y; Ooi, S; Urushidani, Y | 1 |
| Azab, AK; Bahlis, NJ; Boise, LH; Brentnall, M; Duggan, P; Ghobrial, IM; Gratton, K; Klimowicz, AC; Lin, C; Mansoor, A; Neri, P; Ren, L; Stewart, DA; Tassone, P | 1 |
| Chiriva-Internati, M; Chui, K; Cobos, E; Jenkins, MR; John, CM; Mirandola, L; Yu, Y | 1 |
| Andrade, VC; Atanackovic, D; Caballero, OL; Camargo, AA; Colleoni, GW; Costa, ET; de Carvalho, F; Gregorio, JC; Masotti, C; Strauss, BE | 1 |
| Kang, SG; Kim, SG; Lee, WH; Lee, YH; Lee, YS | 1 |
| Pan, XJ; Xiao, W; Yang, ZH; Zheng, CY; Zhou, SY; Zhu, MX | 1 |
| An, N; Chen, SL; Hu, Y; Li, X; Liu, XH; Sun, WJ; Zhang, JJ; Zhong, YP | 1 |
| Chen, LT; Chen, SH; Chen, TJ; Hsing, CH; Huang, HY; Lee, HH; Lee, SW; Li, CF; Lin, CY; Lin, LC; Pan, HY; Sheu, MJ; Shiue, YL; Tian, YF | 1 |
| Cooper, C; Liu, GY; Murphy, LC; Niu, YL; Santos, S; Watson, PH | 1 |
| Eicher, C; Heller, G; Kelly, WK; Morris, MJ; Ryan, C; Scher, HI; Slovin, S | 1 |
| Adler, AS; Chang, HY; Lin, M; Nuyten, DS; Regev, A; Segal, E; van de Vijver, MJ; Wong, DJ | 1 |
| Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
| Hirahara, N; Minari, Y; Nio, Y; Ohmori, H; Sasaki, S; Takamura, M; Tamura, K | 1 |
| Ansari, RH; Brockstein, BE; Garcia, JC; Mani, S; Meyer, SC; Mick, R; Ratain, MJ; Rhinehart, SN; Schilsky, RL; Stadler, WM; Taber, D; Vogelzang, NJ; Vokes, EE | 1 |
2 trial(s) available for pyrazines and Invasiveness, Neoplasm
| Article | Year |
|---|---|
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Risk Assessment; Survival Rate; Treatment Outcome | 2007 |
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pyrazines; Survival Rate | 1998 |
23 other study(ies) available for pyrazines and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Benzamides; Carcinogenesis; Caspase 3; Cell Line, Tumor; Cell Movement; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neuroblastoma; Phenotype; Prognosis; Proto-Oncogene Proteins c-akt; Pyrazines; Spheroids, Cellular; STAT3 Transcription Factor | 2020 |
Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Damage; DNA Repair; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; GPI-Linked Proteins; Heterografts; Humans; Male; Methylation; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Neuropeptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; TOR Serine-Threonine Kinases; Tumor Burden | 2021 |
Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Pyrazines | 2017 |
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Checkpoint Kinase 1; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome; United States; Young Adult | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Decompression, Surgical; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Invasiveness; Prognosis; Pyrazines; Retrospective Studies; Spinal Canal; Spinal Cord Compression; Treatment Outcome | 2015 |
Inhibition of cancer cell migration and invasion through suppressing the Wnt1-mediating signal pathway by G-quadruplex structure stabilizers.
Topics: beta Catenin; Carbazoles; Cell Line, Tumor; Cell Movement; G-Quadruplexes; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Matrix Metalloproteinase 7; Neoplasm Invasiveness; Oligonucleotides; Promoter Regions, Genetic; Pyrazines; Pyridinium Compounds; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Survivin; Wnt1 Protein | 2014 |
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Oxidation-Reduction; Protein Disulfide-Isomerases; Proteins; Pyrazines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Up-Regulation | 2014 |
Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cyclin D3; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4F; Eukaryotic Initiation Factor-4G; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imidazoles; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Phosphoproteins; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-myc; Pyrazines; RNA Caps; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2015 |
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cadherins; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Movement; Epithelial Cells; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mesoderm; Neoplasm Invasiveness; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA, Messenger; Spheroids, Cellular; Time Factors; Transfection; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation; Vorinostat | 2010 |
[A case of aggressive multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prednisolone; Pyrazines | 2011 |
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Boronic Acids; Bortezomib; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Fibronectins; Focal Adhesion Kinase 1; Gene Knockdown Techniques; Gene Silencing; Humans; Integrin beta Chains; Melphalan; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-maf; Pyrazines; rac1 GTP-Binding Protein; src-Family Kinases; Stem Cell Transplantation; Sumoylation; Transcription Factor RelA; Transplantation, Autologous; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dependovirus; Drug Synergism; Endothelial Cells; Fibroblast Growth Factor 2; Galectin 3; Green Fluorescent Proteins; Humans; Immunoglobulin E; Immunoglobulin lambda-Chains; Integrin alphaVbeta3; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Umbilical Veins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Proliferation; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering | 2011 |
Hypoxia-inducible factor-1α inhibition by a pyrrolopyrazine metabolite of oltipraz as a consequence of microRNAs 199a-5p and 20a induction.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; HT29 Cells; Humans; Hydrogen Peroxide; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; MicroRNAs; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Pyridazines; Pyrroles; Thiones; Thiophenes | 2012 |
Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Immunoglobulin G; Lung Neoplasms; Matrix Metalloproteinase 2; Melphalan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
[Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Plasmacytoma; Prognosis; Pyrazines; Retrospective Studies | 2012 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Rectal Neoplasms; Retrospective Studies; S-Phase Kinase-Associated Proteins; Survival Rate; Tumor Cells, Cultured | 2013 |
Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Topics: Antigens, Neoplasm; Blotting, Western; Boronic Acids; Bortezomib; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Intraductal, Noninfiltrating; Cell Hypoxia; Cell Survival; Down-Regulation; Estrogen Receptor alpha; Female; Glucose Transporter Type 1; Humans; Immunoenzyme Techniques; Monosaccharide Transport Proteins; Neoplasm Invasiveness; Oxygen; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Revealing targeted therapy for human cancer by gene module maps.
Topics: Algorithms; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Chromosome Mapping; Electronic Data Processing; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Targeting; Genes, Mitochondrial; Genetic Therapy; Humans; Neoplasm Invasiveness; Neoplasms; Oligonucleotide Array Sequence Analysis; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured; Wounds and Injuries | 2008 |
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebellum; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Meninges; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Staging; Plasma Cells; Pyrazines; Skin | 2008 |
A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteoglycans; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |